Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2730-2735

  Mendes Pereira, Ana M ^a   Sims, David ^a   Dexter, Tim ^a   Fenwick, Kerry ^a   Assiotis, Ioannis ^a   Kozarewa, Iwanka ^a   Mitsopoulos, Costas ^a   Hakas, Jarle ^a   Zvelebil, Marketa ^a   Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Endocrine therapy; Genetics; Next generation sequencing; RNA interference screening

Indexed keywords

BAP1 PROTEIN; EDF1 PROTEIN; ENDOPEPTIDASE CLP; GPRC5D PROTEIN; ING5 PROTEIN; K RAS PROTEIN; NAE1 PROTEIN; NF1 PROTEIN; NIPBL PROTEIN; NOC3L PROTEIN; NSD1 PROTEIN; NUT PROTEIN; PPP1R15B PROTEIN; PROTEIN; RAD21 PROTEIN; RARG PROTEIN; RAS PROTEIN; RRAS2 PROTEIN; SHORT HAIRPIN RNA; SMC3 PROTEIN; TAMOXIFEN; TMPRSS2 PROTEIN; TPM4 PROTEIN; UBA3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC SCREENING; PRIORITY JOURNAL; PROTEIN DENATURATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, NEOPLASM; GENETIC TESTING; GENOME, HUMAN; HUMANS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84857377978     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018872108     Document Type: Article

References (37)

1. EBCTCG (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467.
2. Frasor J, et al. (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574. (Pubitemid 37204856)
3. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074-1080. (Pubitemid 32758077)
4. Sabbah M, Courilleau D, Mester J, Redeuilh G (1999) Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element. Proc Natl Acad Sci USA 96:11217-11222. (Pubitemid 29487361)
5. Dubik D, Shiu RP (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263: 12705-12708. (Pubitemid 19000455)
6. Beatson G (1896) On the treatment of inoperable cases of carcinoma of the mammary. Suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107.
7. Cole MP, Jones CT, Todd ID (1971) A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25:270-275.
8. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643-658. (Pubitemid 40065543)
9. Shou J, et al. (2004) Mechanisms of tamoxifen resistance: Increased estrogen receptor- HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935. (Pubitemid 38868139)
10. Oh AS, et al. (2001) Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15:1344-1359. (Pubitemid 32703482)
11. Gee JM, Robertson JF, Ellis IO, Nicholson RI (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254. (Pubitemid 32592092)
12. Pérez-Tenorio G, Stål O; Southeast Sweden Breast Cancer Group (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545. (Pubitemid 34185089)
13. Holm C, et al. (2006) Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98:671-680. (Pubitemid 43821785)
14. Campbell RA, et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824.
15. Iorns E, et al. (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13:91-104. (Pubitemid 351163160)
16. Boutros M, Ahringer J (2008) The art and design of genetic screens: RNA interference. Nat Rev Genet 9:554-566. (Pubitemid 351861541)
17. Luo B, et al. (2008) Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105:20380-20385.
18. Echeverri CJ, et al. (2006) Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 3:777-779. (Pubitemid 44445821)
19. Snel B, Lehmann G, Bork P, Huynen MA (2000) STRING: A web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res 28: 3442-3444.
20. Gong L, Yeh ET (1999) Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem 274:12036-12042.
21. Jones SE (2002) A new estrogen receptor antagonist - an overview of available data. Breast Cancer Res Treat 75(Suppl 1):S19-S21; discussion S33-S35.
22. Fan M, Bigsby RM, Nephew KP (2003) The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol 17:356-365. (Pubitemid 36315630)
23. Schmidt D, et al. (2010) A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 20:578-588.
24. Hakimi MA, et al. (2002) A chromatin remodelling complex that loads cohesin onto human chromosomes. Nature 418:994-998. (Pubitemid 34976036)
25. Liu J, et al. (2009) Transcriptional dysregulation in NIPBL and cohesin mutant human cells. PLoS Biol 7:e1000119.
26. Huang Y, et al. (2004) Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells. Oncogene 23:368-378. (Pubitemid 38174990)
27. Pawitan Y, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res 7:R953-R964.
28. Loi S, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246. (Pubitemid 46640570)
29. Miller LD, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550-13555. (Pubitemid 41420886)
30. Loi S, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239.
31. Cox DR (1972) Regression models and life tables. J R Stat Soc, B 34:187-220.
32. Juul N, et al. (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: A retrospective analysis of five clinical trials. Lancet Oncol 11:358-365.
33. Iorns E, Lord CJ, Ashworth A (2009) Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 417:361-370.
34. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG (1997) Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15:423-435. (Pubitemid 27370992)
35. Calvo F, Crespo P (2009) Structural and spatial determinants regulating TC21 activation by RasGRF family nucleotide exchange factors. Mol Biol Cell 20:4289-4302.
36. Rokavec M, et al. (2008) A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer. Cancer Res 68: 9799-9808.
37. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193. (Pubitemid 36181903)